{"transactions":[{"id":4623588,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-21T21:22:07.000Z","date":"2026-09-17","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":106268,"derivative":{"exercise_price":2.48,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001701247-26-000013","document":"form4-09212026_090903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1701247/000170124726000013/form4-09212026_090903.xml","form_type":"4"}},{"id":4623587,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-21T21:22:07.000Z","date":"2026-09-17","kind":"sale","planned":true,"acquired":false,"shares":240,"price":51.482,"value":12355.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $51.365 to $51.675. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001701247-26-000013","document":"form4-09212026_090903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701247/000170124726000013/form4-09212026_090903.xml","form_type":"4"}},{"id":4623586,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-21T21:22:07.000Z","date":"2026-09-17","kind":"sale","planned":true,"acquired":false,"shares":1844,"price":50.7089,"value":93507.2116,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $50.3099 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":25240,"source":{"system":"sec-edgar","filing":"0001701247-26-000013","document":"form4-09212026_090903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701247/000170124726000013/form4-09212026_090903.xml","form_type":"4"}},{"id":4623585,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-21T21:22:07.000Z","date":"2026-09-17","kind":"sale","planned":true,"acquired":false,"shares":2916,"price":50.0312,"value":145890.9792,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $49.305 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":27084,"source":{"system":"sec-edgar","filing":"0001701247-26-000013","document":"form4-09212026_090903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701247/000170124726000013/form4-09212026_090903.xml","form_type":"4"}},{"id":4623584,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-21T21:22:07.000Z","date":"2026-09-17","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":2.48,"value":12400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001701247-26-000013","document":"form4-09212026_090903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701247/000170124726000013/form4-09212026_090903.xml","form_type":"4"}},{"id":681395,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-19T20:16:13.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":111268,"derivative":{"exercise_price":2.48,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001701247-26-000012","document":"form4-08192026_080807.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000012/form4-08192026_080807.xml","form_type":"4"}},{"id":681394,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-08-19T20:16:13.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":1100,"price":59.3465,"value":65281.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $58.985 to $59.535. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001701247-26-000012","document":"form4-08192026_080807.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000012/form4-08192026_080807.xml","form_type":"4"}},{"id":681393,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-08-19T20:16:13.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":3900,"price":58.3717,"value":227649.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $57.895 to $58.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":26100,"source":{"system":"sec-edgar","filing":"0001701247-26-000012","document":"form4-08192026_080807.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000012/form4-08192026_080807.xml","form_type":"4"}},{"id":681392,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-08-19T20:16:13.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":2.48,"value":12400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001701247-26-000012","document":"form4-08192026_080807.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000012/form4-08192026_080807.xml","form_type":"4"}},{"id":705190,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-21T21:23:03.000Z","date":"2026-07-17","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":116268,"derivative":{"exercise_price":2.48,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001701247-26-000011","document":"form4-07212026_090758.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000011/form4-07212026_090758.xml","form_type":"4"}},{"id":705189,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-07-21T21:23:03.000Z","date":"2026-07-17","kind":"sale","planned":true,"acquired":false,"shares":63,"price":53.9208,"value":3397.0104,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This transaction was executed in multiple trades at prices ranging from $53.8793 to $53.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001701247-26-000011","document":"form4-07212026_090758.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000011/form4-07212026_090758.xml","form_type":"4"}},{"id":705188,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-07-21T21:23:03.000Z","date":"2026-07-17","kind":"sale","planned":true,"acquired":false,"shares":2184,"price":53.4199,"value":116669.0616,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This transaction was executed in multiple trades at prices ranging from $52.8741 to $53.8708. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":25063,"source":{"system":"sec-edgar","filing":"0001701247-26-000011","document":"form4-07212026_090758.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000011/form4-07212026_090758.xml","form_type":"4"}},{"id":705187,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-07-21T21:23:03.000Z","date":"2026-07-17","kind":"sale","planned":true,"acquired":false,"shares":2063,"price":52.3921,"value":108084.9023,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $51.8711 to $52.845. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":27247,"source":{"system":"sec-edgar","filing":"0001701247-26-000011","document":"form4-07212026_090758.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000011/form4-07212026_090758.xml","form_type":"4"}},{"id":705186,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-07-21T21:23:03.000Z","date":"2026-07-17","kind":"sale","planned":true,"acquired":false,"shares":459,"price":51.5466,"value":23659.8894,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $50.85 to $51.8305. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":29310,"source":{"system":"sec-edgar","filing":"0001701247-26-000011","document":"form4-07212026_090758.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000011/form4-07212026_090758.xml","form_type":"4"}},{"id":705185,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-07-21T21:23:03.000Z","date":"2026-07-17","kind":"sale","planned":true,"acquired":false,"shares":231,"price":50.0542,"value":11562.5202,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $49.72 to $50.3565. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":29769,"source":{"system":"sec-edgar","filing":"0001701247-26-000011","document":"form4-07212026_090758.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000011/form4-07212026_090758.xml","form_type":"4"}},{"id":705184,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-07-21T21:23:03.000Z","date":"2026-07-17","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":2.48,"value":12400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001701247-26-000011","document":"form4-07212026_090758.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000011/form4-07212026_090758.xml","form_type":"4"}},{"id":730481,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-06-22T21:11:57.000Z","date":"2026-06-17","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":121268,"derivative":{"exercise_price":2.48,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001701247-26-000010","document":"form4-06222026_090652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000010/form4-06222026_090652.xml","form_type":"4"}},{"id":730480,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-06-22T21:11:57.000Z","date":"2026-06-17","kind":"sale","planned":true,"acquired":false,"shares":1133,"price":44.743,"value":50693.819,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $44.3005 to $44.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001701247-26-000010","document":"form4-06222026_090652.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000010/form4-06222026_090652.xml","form_type":"4"}},{"id":730479,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-06-22T21:11:57.000Z","date":"2026-06-17","kind":"sale","planned":true,"acquired":false,"shares":2599,"price":43.8701,"value":114018.3899,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $43.30 to $44.2925. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":26133,"source":{"system":"sec-edgar","filing":"0001701247-26-000010","document":"form4-06222026_090652.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000010/form4-06222026_090652.xml","form_type":"4"}},{"id":730478,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-06-22T21:11:57.000Z","date":"2026-06-17","kind":"sale","planned":true,"acquired":false,"shares":1268,"price":42.827,"value":54304.636,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $42.295 to $43.2752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":28732,"source":{"system":"sec-edgar","filing":"0001701247-26-000010","document":"form4-06222026_090652.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000010/form4-06222026_090652.xml","form_type":"4"}},{"id":730477,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-06-22T21:11:57.000Z","date":"2026-06-17","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":2.48,"value":12400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001701247-26-000010","document":"form4-06222026_090652.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000010/form4-06222026_090652.xml","form_type":"4"}},{"id":749459,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2026-06-04T22:30:10.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":35000,"derivative":{"exercise_price":8.77,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-257900","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526257900/ownership.xml","form_type":"4"}},{"id":770020,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-20T20:18:52.000Z","date":"2026-05-18","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":126268,"derivative":{"exercise_price":2.48,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001701247-26-000007","document":"form4-05202026_080544.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000007/form4-05202026_080544.xml","form_type":"4"}},{"id":770019,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-05-20T20:18:52.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":223,"price":41.2052,"value":9188.7596,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $40.8625 to $41.605. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001701247-26-000007","document":"form4-05202026_080544.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000007/form4-05202026_080544.xml","form_type":"4"}},{"id":770018,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-05-20T20:18:52.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":1302,"price":40.2473,"value":52401.9846,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $39.855 to $40.83. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":25223,"source":{"system":"sec-edgar","filing":"0001701247-26-000007","document":"form4-05202026_080544.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000007/form4-05202026_080544.xml","form_type":"4"}},{"id":770017,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-05-20T20:18:52.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":3475,"price":39.534,"value":137380.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $38.855 to $39.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":26525,"source":{"system":"sec-edgar","filing":"0001701247-26-000007","document":"form4-05202026_080544.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000007/form4-05202026_080544.xml","form_type":"4"}},{"id":770016,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-05-20T20:18:52.000Z","date":"2026-05-18","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":2.48,"value":12400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001701247-26-000007","document":"form4-05202026_080544.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000007/form4-05202026_080544.xml","form_type":"4"}},{"id":803720,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T00:40:17.000Z","date":"2026-04-17","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":131268,"derivative":{"exercise_price":2.48,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001701247-26-000006","document":"form4-04222026_120411.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000006/form4-04222026_120411.xml","form_type":"4"}},{"id":803719,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-04-22T00:40:17.000Z","date":"2026-04-17","kind":"sale","planned":true,"acquired":false,"shares":2441,"price":48.0555,"value":117303.4755,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $47.8303 to $48.4936. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001701247-26-000006","document":"form4-04222026_120411.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000006/form4-04222026_120411.xml","form_type":"4"}},{"id":803718,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-04-22T00:40:17.000Z","date":"2026-04-17","kind":"sale","planned":true,"acquired":false,"shares":2419,"price":47.3896,"value":114635.4424,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $46.8218 to $47.8166. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":27441,"source":{"system":"sec-edgar","filing":"0001701247-26-000006","document":"form4-04222026_120411.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000006/form4-04222026_120411.xml","form_type":"4"}},{"id":803717,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-04-22T00:40:17.000Z","date":"2026-04-17","kind":"sale","planned":true,"acquired":false,"shares":140,"price":45.8107,"value":6413.498,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $45.525 to $46.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":29860,"source":{"system":"sec-edgar","filing":"0001701247-26-000006","document":"form4-04222026_120411.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000006/form4-04222026_120411.xml","form_type":"4"}},{"id":803716,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-04-22T00:40:17.000Z","date":"2026-04-17","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":2.48,"value":12400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001701247-26-000006","document":"form4-04222026_120411.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000006/form4-04222026_120411.xml","form_type":"4"}},{"id":826348,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-27T20:57:22.000Z","date":"2026-03-25","kind":"exercise","planned":true,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":136268,"derivative":{"exercise_price":2.48,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001701247-26-000005","document":"form4-03272026_080317.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000005/form4-03272026_080317.xml","form_type":"4"}},{"id":826347,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-27T20:57:22.000Z","date":"2026-03-25","kind":"sale","planned":true,"acquired":false,"shares":40000,"price":35.1006,"value":1404024.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $35.00 to $35.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001701247-26-000005","document":"form4-03272026_080317.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000005/form4-03272026_080317.xml","form_type":"4"}},{"id":826346,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-27T20:57:22.000Z","date":"2026-03-25","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":2.48,"value":99200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":65000,"source":{"system":"sec-edgar","filing":"0001701247-26-000005","document":"form4-03272026_080317.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000005/form4-03272026_080317.xml","form_type":"4"}},{"id":833488,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-19T21:50:52.000Z","date":"2026-03-17","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":176268,"derivative":{"exercise_price":2.48,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001701247-26-000004","document":"form4-03192026_090347.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000004/form4-03192026_090347.xml","form_type":"4"}},{"id":833487,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-19T21:50:52.000Z","date":"2026-03-17","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":27.76,"value":138800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $27.40 to $28.2278. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001701247-26-000004","document":"form4-03192026_090347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000004/form4-03192026_090347.xml","form_type":"4"}},{"id":833486,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-19T21:50:52.000Z","date":"2026-03-17","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":2.48,"value":12400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001701247-26-000004","document":"form4-03192026_090347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000004/form4-03192026_090347.xml","form_type":"4"}},{"id":848672,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-11T21:32:25.000Z","date":"2026-03-10","kind":"exercise","planned":true,"acquired":false,"shares":10129,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":181268,"derivative":{"exercise_price":2.48,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":10129},"source":{"system":"sec-edgar","filing":"0001701247-26-000003","document":"form4-03112026_090319.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000003/form4-03112026_090319.xml","form_type":"4"}},{"id":848671,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-11T21:32:25.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":29871,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":191397,"derivative":{"exercise_price":2.48,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":29871},"source":{"system":"sec-edgar","filing":"0001701247-26-000003","document":"form4-03112026_090319.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000003/form4-03112026_090319.xml","form_type":"4"}},{"id":848670,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-11T21:32:25.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":10129,"price":30.1932,"value":305826.9228,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $30.00 to $30.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001701247-26-000003","document":"form4-03112026_090319.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000003/form4-03112026_090319.xml","form_type":"4"}},{"id":848669,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-11T21:32:25.000Z","date":"2026-03-10","kind":"exercise","planned":true,"acquired":true,"shares":10129,"price":2.48,"value":25119.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":35129,"source":{"system":"sec-edgar","filing":"0001701247-26-000003","document":"form4-03112026_090319.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000003/form4-03112026_090319.xml","form_type":"4"}},{"id":848668,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-11T21:32:25.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":29871,"price":30.0228,"value":896811.0588,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $30.00 to $30.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001701247-26-000003","document":"form4-03112026_090319.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000003/form4-03112026_090319.xml","form_type":"4"}},{"id":848667,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-03-11T21:32:25.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":29871,"price":2.48,"value":74080.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":54871,"source":{"system":"sec-edgar","filing":"0001701247-26-000003","document":"form4-03112026_090319.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000003/form4-03112026_090319.xml","form_type":"4"}},{"id":893381,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-19T23:36:48.000Z","date":"2026-02-17","kind":"exercise","planned":true,"acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":221268,"derivative":{"exercise_price":2.48,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001701247-26-000002","document":"form4-02192026_110242.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000002/form4-02192026_110242.xml","form_type":"4"}},{"id":893380,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-19T23:36:48.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":45000,"price":26.1747,"value":1177861.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $25.76 to $26.695. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001701247-26-000002","document":"form4-02192026_110242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000002/form4-02192026_110242.xml","form_type":"4"}},{"id":893379,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-19T23:36:48.000Z","date":"2026-02-17","kind":"exercise","planned":true,"acquired":true,"shares":45000,"price":2.48,"value":111600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025."}],"balance_after":70000,"source":{"system":"sec-edgar","filing":"0001701247-26-000002","document":"form4-02192026_110242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000002/form4-02192026_110242.xml","form_type":"4"}},{"id":901011,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-18T00:47:55.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":150000,"derivative":{"exercise_price":27.16,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001701247-26-000001","document":"form4-02182026_120250.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000001/form4-02182026_120250.xml","form_type":"4"}},{"id":901010,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-18T00:47:55.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001701247-26-000001","document":"form4-02182026_120250.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000170124726000001/form4-02182026_120250.xml","form_type":"4"}},{"id":1119907,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:24:53.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":35144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":35144,"derivative":{"exercise_price":1.5,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":35144},"source":{"system":"sec-edgar","filing":"0000905148-25-002029","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514825002029/form4.xml","form_type":"4"}},{"id":1119470,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2025-06-06T20:05:24.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":28500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":28500,"derivative":{"exercise_price":6.57,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0000950170-25-083041","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017025083041/ownership.xml","form_type":"4"}},{"id":1276592,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-10T22:25:35.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":171000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option will vest on February 6, 2026 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":171000,"derivative":{"exercise_price":22.47,"expiration_date":"2035-02-06","underlying":"Common Stock","underlying_shares":171000},"source":{"system":"sec-edgar","filing":"0001415889-25-003509","document":"form4-02102025_100231.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588925003509/form4-02102025_100231.xml","form_type":"4"}},{"id":1382944,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-10-22T20:17:41.000Z","date":"2024-10-18","kind":"exercise","planned":true,"acquired":false,"shares":816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option, originally for 287,084 shares, vested as to one-fourth of the shares on June 17, 2022, and the remainder vest in 36 equal monthly installments thereafter."}],"balance_after":266268,"derivative":{"exercise_price":2.48,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":816},"source":{"system":"sec-edgar","filing":"0001415889-24-025499","document":"form4-10222024_081038.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924025499/form4-10222024_081038.xml","form_type":"4"}},{"id":1382943,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-10-22T20:17:41.000Z","date":"2024-10-18","kind":"sale","planned":true,"acquired":false,"shares":816,"price":30.003,"value":24482.448,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-025499","document":"form4-10222024_081038.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924025499/form4-10222024_081038.xml","form_type":"4"}},{"id":1382942,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-10-22T20:17:41.000Z","date":"2024-10-18","kind":"exercise","planned":true,"acquired":true,"shares":816,"price":2.48,"value":2023.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."}],"balance_after":816,"source":{"system":"sec-edgar","filing":"0001415889-24-025499","document":"form4-10222024_081038.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924025499/form4-10222024_081038.xml","form_type":"4"}},{"id":1486602,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2024-06-07T20:30:02.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":26000,"derivative":{"exercise_price":21.79,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0000950170-24-070697","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017024070697/ownership.xml","form_type":"4"}},{"id":1487110,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:12:22.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":45642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":45642,"derivative":{"exercise_price":1.25,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":45642},"source":{"system":"sec-edgar","filing":"0000905148-24-001682","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514824001682/form4.xml","form_type":"4"}},{"id":1541898,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-15T23:02:46.000Z","date":"2024-04-11","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option, originally for 287,084 shares, vested as to one-fourth of the shares on June 17, 2022, and the remainder vest in 36 equal monthly installments thereafter."}],"balance_after":267084,"derivative":{"exercise_price":2.48,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-24-010823","document":"form4-04152024_110437.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924010823/form4-04152024_110437.xml","form_type":"4"}},{"id":1541897,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-04-15T23:02:46.000Z","date":"2024-04-11","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":25.0739,"value":501478.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $25.00 to $25.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-010823","document":"form4-04152024_110437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924010823/form4-04152024_110437.xml","form_type":"4"}},{"id":1541896,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-04-15T23:02:46.000Z","date":"2024-04-11","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":2.48,"value":49600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001415889-24-010823","document":"form4-04152024_110437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924010823/form4-04152024_110437.xml","form_type":"4"}},{"id":1640964,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-16T01:46:29.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option will vest on February 13, 2025 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":185000,"derivative":{"exercise_price":14.85,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":185000},"source":{"system":"sec-edgar","filing":"0001415889-24-004012","document":"form4-02162024_010221.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924004012/form4-02162024_010221.xml","form_type":"4"}},{"id":1737036,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-17T21:47:01.000Z","date":"2023-11-15","kind":"grant","planned":false,"acquired":true,"shares":64238,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of these options vest each month over three years, subject to the reporting person's continued service through each applicable vesting date, and subject to 100% acceleration upon a change of control."}],"balance_after":64238,"derivative":{"exercise_price":0.98,"expiration_date":"2033-11-15","underlying":"Common Stock","underlying_shares":64238},"source":{"system":"sec-edgar","filing":"0000905148-23-001485","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000090514823001485/form4.xml","form_type":"4"}},{"id":1869493,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-06-02T20:45:02.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":26000,"derivative":{"exercise_price":13.32,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001209191-23-033836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919123033836/doc4.xml","form_type":"4"}},{"id":1923782,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-07T00:32:07.000Z","date":"2023-04-04","kind":"grant","planned":false,"acquired":true,"shares":206000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option will vest on February 23, 2024 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date"}],"balance_after":206000,"derivative":{"exercise_price":22.75,"expiration_date":"2033-04-04","underlying":"Common Stock","underlying_shares":206000},"source":{"system":"sec-edgar","filing":"0001209191-23-023676","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123023676/doc4.xml","form_type":"4"}},{"id":1990379,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-28T02:32:25.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":287084,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the \"Merger Agreement\"), by and among Imara Inc. (\"Imara\"), Enliven Therapeutics, Inc., (\"Enliven\") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the \"Merger Sub\"), each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock (rounded down to the nearest whole share number), (footnote continued in footnote (3))"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from footnote (2)): with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the option vested on June 17, 2022, and the remainder vest in 36 equal monthly installments thereafter."}],"balance_after":287084,"derivative":{"exercise_price":2.48,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":287084},"source":{"system":"sec-edgar","filing":"0001209191-23-013492","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123013492/doc4.xml","form_type":"4"}},{"id":2222967,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2022-06-23T20:54:30.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":14.84,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-22-038944","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919122038944/doc4.xml","form_type":"4"}},{"id":2622077,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2021-07-29T21:17:06.000Z","date":"2021-07-28","kind":"grant","acquired":true,"shares":19166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":19166,"derivative":{"exercise_price":18.98,"expiration_date":"2031-07-27","underlying":"Common Stock","underlying_shares":19166},"source":{"system":"sec-edgar","filing":"0001209191-21-048540","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919121048540/doc4.xml","form_type":"4"}},{"id":2622076,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2021-07-29T21:17:06.000Z","date":"2021-07-28","kind":"grant","acquired":true,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in three equal annual installments commencing on the one year anniversary of the date of grant."}],"balance_after":46000,"derivative":{"exercise_price":18.98,"expiration_date":"2031-07-27","underlying":"Common Stock","underlying_shares":46000},"source":{"system":"sec-edgar","filing":"0001209191-21-048540","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919121048540/doc4.xml","form_type":"4"}},{"id":2745473,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-19T19:53:58.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":5.25,"underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-21-027421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027421/doc4.xml","form_type":"4"}},{"id":2745472,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-19T19:53:58.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":5.25,"underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-21-027421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027421/doc4.xml","form_type":"4"}},{"id":2745471,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-19T19:53:58.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":5.78,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-027421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027421/doc4.xml","form_type":"4"}},{"id":2745470,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-19T19:53:58.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":58000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":11.97,"underlying":"Common Stock","underlying_shares":58000},"source":{"system":"sec-edgar","filing":"0001209191-21-027421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027421/doc4.xml","form_type":"4"}},{"id":2745469,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-19T19:53:58.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":18.69,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-027421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027421/doc4.xml","form_type":"4"}},{"id":2745468,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-19T19:53:58.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of Common Stock granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":37.89,"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-21-027421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027421/doc4.xml","form_type":"4"}},{"id":2745467,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-19T19:53:58.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":135547,"price":38,"value":5150786.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, each issued and outstanding share of common stock of the Company, par value $0.001 per share (\"Common Stock\"), was converted into the right to receive $38.00 per share (the \"Offer Price\") in cash, without interest, minus any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-027421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027421/doc4.xml","form_type":"4"}},{"id":2745466,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-19T19:53:58.000Z","date":"2021-04-16","kind":"grant","acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of performance-based restricted Common Stock (as defined below) granted to the reporting person on June 24, 2019 (the \"Performance Award\"). The performance conditions associated with the Performance Award have not yet occurred. Pursuant to the Merger Agreement (as defined below), immediately prior to the effective time of the Merger (as defined below), the Performance Award was deemed to have vested and each share of Common Stock underlying the Performance Award was converted into the right to receive the Offer Price (as defined below) in cash, without interest, minus any applicable withholding taxes."}],"balance_after":135547,"source":{"system":"sec-edgar","filing":"0001209191-21-027421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027421/doc4.xml","form_type":"4"}},{"id":2745465,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-19T19:53:58.000Z","date":"2021-03-31","kind":"gift","acquired":false,"shares":8085,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":69547,"source":{"system":"sec-edgar","filing":"0001209191-21-027421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027421/doc4.xml","form_type":"4"}},{"id":2821039,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-02T12:08:35.000Z","date":"2021-02-26","kind":"tax_withholding","acquired":false,"shares":1158,"price":22.23,"value":25742.34,"ownership":{"direct":true},"balance_after":77632,"source":{"system":"sec-edgar","filing":"0001209191-21-015609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121015609/doc4.xml","form_type":"4"}},{"id":2830074,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-26T14:36:57.000Z","date":"2021-02-25","kind":"tax_withholding","acquired":false,"shares":1653,"price":23.08,"value":38151.24,"ownership":{"direct":true},"balance_after":78790,"source":{"system":"sec-edgar","filing":"0001209191-21-014644","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121014644/doc4.xml","form_type":"4"}},{"id":2830073,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-26T14:36:57.000Z","date":"2021-02-24","kind":"tax_withholding","acquired":false,"shares":5091,"price":25.71,"value":130889.61,"ownership":{"direct":true},"balance_after":80443,"source":{"system":"sec-edgar","filing":"0001209191-21-014644","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121014644/doc4.xml","form_type":"4"}},{"id":2944893,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance-Based Restricted Common Stock","published_at":"2020-12-15T12:00:43.000Z","date":"2020-12-11","kind":"exercise","acquired":false,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares subject to this grant vest upon achievement of certain performance conditions, as further described in the other footnotes to this report."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents 50% of the shares subject to this award, which shares vested on the date that the 30-calendar-day volume-weighted average closing\nprice of a share of common stock of the Company was greater than or equal to $19.43."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"50% of the shares subject to this award vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company was greater than or equal to $12.95, and the remaining 50% of the shares subject to this award vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company was greater than or equal to $19.43."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"50% of the shares subject to this award vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company was greater than or equal to $12.95, and the remaining 50% of the shares subject to this award vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company was greater than or equal to $19.43."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-20-063389","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120063389/doc4.xml","form_type":"4"}},{"id":2944892,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-15T12:00:43.000Z","date":"2020-12-11","kind":"tax_withholding","acquired":false,"shares":11583,"price":16.14,"value":186949.62,"ownership":{"direct":true},"balance_after":85534,"source":{"system":"sec-edgar","filing":"0001209191-20-063389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120063389/doc4.xml","form_type":"4"}},{"id":2944891,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-15T12:00:43.000Z","date":"2020-12-11","kind":"exercise","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of performance-based restricted common stock granted to the reporting person on June 24, 2019. These shares vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of Five Prime Therapeutics, Inc. (the \"Company\") was greater than or equal to $19.43."}],"balance_after":97117,"source":{"system":"sec-edgar","filing":"0001209191-20-063389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120063389/doc4.xml","form_type":"4"}},{"id":2981603,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Performance-Based Restricted Common Stock","published_at":"2020-11-13T12:25:37.000Z","date":"2020-11-11","kind":"exercise","acquired":false,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares subject to this grant vest upon achievement of certain performance conditions, as further described in the other footnotes to this report."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents 50% of the shares subject to this award, which shares vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company was greater than or equal to $12.95."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The remaining shares subject to this award will vest on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company is greater than or equal to $19.43, subject to the reporting person's continued service to the Company through such date; provided that such shares shall automatically expire and be forfeited if such shares have not vested by December 31, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The remaining shares subject to this award will vest on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company is greater than or equal to $19.43, subject to the reporting person's continued service to the Company through such date; provided that such shares shall automatically expire and be forfeited if such shares have not vested by December 31, 2021."}],"balance_after":22000,"derivative":{"underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-20-058237","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120058237/doc4.xml","form_type":"4"}},{"id":2981602,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-13T12:25:37.000Z","date":"2020-11-11","kind":"tax_withholding","acquired":false,"shares":11039,"price":18,"value":198702.0,"ownership":{"direct":true},"balance_after":75117,"source":{"system":"sec-edgar","filing":"0001209191-20-058237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120058237/doc4.xml","form_type":"4"}},{"id":2981601,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-13T12:25:37.000Z","date":"2020-11-11","kind":"exercise","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of performance-based restricted common stock granted to the reporting person on June 24, 2019. These shares vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of Five Prime Therapeutics, Inc. (the \"Company\") was greater than or equal to $12.95."}],"balance_after":86156,"source":{"system":"sec-edgar","filing":"0001209191-20-058237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120058237/doc4.xml","form_type":"4"}},{"id":3048922,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-08-24T13:46:09.000Z","date":"2020-08-20","kind":"tax_withholding","acquired":false,"shares":827,"price":4.69,"value":3878.63,"ownership":{"direct":true},"balance_after":64156,"source":{"system":"sec-edgar","filing":"0001209191-20-048041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120048041/doc4.xml","form_type":"4"}},{"id":3198122,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-03-23T12:11:05.000Z","date":"2020-03-20","kind":"tax_withholding","acquired":false,"shares":827,"price":2.3,"value":1902.1,"ownership":{"direct":true},"balance_after":64983,"source":{"system":"sec-edgar","filing":"0001209191-20-020592","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120020592/doc4.xml","form_type":"4"}},{"id":3246574,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-02-26T20:22:53.000Z","date":"2020-02-24","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the option vest at a rate of one forty-eighth (1/48) per month following February 24, 2020, provided the reporting person provides services to the Company through each such date."}],"balance_after":90000,"derivative":{"exercise_price":5.25,"expiration_date":"2030-02-23","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-20-013272","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120013272/doc4.xml","form_type":"4"}},{"id":3246573,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-02-26T20:22:53.000Z","date":"2020-02-24","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents a retention equity incentive award consisting of options to purchase shares of the Company's common stock. One-fourth (1/4) of the shares underlying this option will vest on February 24, 2021, and the remainder of the shares underlying this option vest at a rate of one forth-eighth (1/48) per month thereafter, provided the reporting person provides services to the Company through each such date."}],"balance_after":90000,"derivative":{"exercise_price":5.25,"expiration_date":"2030-02-23","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-20-013272","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120013272/doc4.xml","form_type":"4"}},{"id":3246572,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-02-26T20:22:53.000Z","date":"2020-02-26","kind":"tax_withholding","acquired":false,"shares":1281,"price":4.83,"value":6187.23,"ownership":{"direct":true},"balance_after":65810,"source":{"system":"sec-edgar","filing":"0001209191-20-013272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120013272/doc4.xml","form_type":"4"}},{"id":3246571,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-02-26T20:22:53.000Z","date":"2020-02-25","kind":"tax_withholding","acquired":false,"shares":1862,"price":4.87,"value":9067.94,"ownership":{"direct":true},"balance_after":67091,"source":{"system":"sec-edgar","filing":"0001209191-20-013272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120013272/doc4.xml","form_type":"4"}},{"id":3246570,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-02-26T20:22:53.000Z","date":"2020-02-24","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 24, 2021, 2022 and 2023, provided the reporting person provides services to the Company through each such date."}],"balance_after":68953,"source":{"system":"sec-edgar","filing":"0001209191-20-013272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120013272/doc4.xml","form_type":"4"}},{"id":3246569,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-02-26T20:22:53.000Z","date":"2020-02-24","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a retention equity incentive award consisting of shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 24, 2021, 2022 and 2023, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the \"Company\") through each such date."}],"balance_after":53953,"source":{"system":"sec-edgar","filing":"0001209191-20-013272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120013272/doc4.xml","form_type":"4"}},{"id":3286783,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-02-06T18:51:24.000Z","date":"2020-02-05","kind":"tax_withholding","acquired":false,"shares":5345,"price":5.13,"value":27419.85,"ownership":{"direct":true},"balance_after":38953,"source":{"system":"sec-edgar","filing":"0001209191-20-007293","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120007293/doc4.xml","form_type":"4"}},{"id":3423453,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-09-04T13:12:47.000Z","date":"2019-09-01","kind":"tax_withholding","acquired":false,"shares":496,"price":5.43,"value":2693.28,"ownership":{"direct":true},"balance_after":44298,"source":{"system":"sec-edgar","filing":"0001209191-19-048073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119048073/doc4.xml","form_type":"4"}},{"id":3431256,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-08-22T18:50:25.000Z","date":"2019-08-20","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest at a rate of one forty-eighth (1/48th) per month following August 20, 2019, provided the reporting person provides services to the Company through each such date."}],"balance_after":20000,"derivative":{"exercise_price":5.78,"expiration_date":"2029-08-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-19-047176","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119047176/doc4.xml","form_type":"4"}},{"id":3431255,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-08-22T18:50:25.000Z","date":"2019-08-20","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of August 20, 2020, 2021 and 2022, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the \"Company\") through each such date."}],"balance_after":44794,"source":{"system":"sec-edgar","filing":"0001209191-19-047176","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119047176/doc4.xml","form_type":"4"}},{"id":3478164,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Medical Officer"}}],"security":"Performance-Based Restricted Common Stock","published_at":"2019-06-26T16:28:37.000Z","date":"2019-06-24","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares will vest upon achievement of certain performance conditions, as further described in Footnote 2."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(i) 50% of the shares subject to this award will vest on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of Five Prime Therapeutics, Inc. (the \"Company\") is greater than or equal to $12.95, provided that such shares shall automatically expire and be forfeited if such shares have not vested by December 31, 2020; and (ii) 50% of the shares subject to this award will vest on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company is greater than or equal to $19.43, provided that such shares shall automatically expire and be forfeited if such shares have not vested by December 31, 2021; in each case, subject to the reporting person's continued service to the Company through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(i) 50% of the shares subject to this award will vest on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of Five Prime Therapeutics, Inc. (the \"Company\") is greater than or equal to $12.95, provided that such shares shall automatically expire and be forfeited if such shares have not vested by December 31, 2020; and (ii) 50% of the shares subject to this award will vest on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company is greater than or equal to $19.43, provided that such shares shall automatically expire and be forfeited if such shares have not vested by December 31, 2021; in each case, subject to the reporting person's continued service to the Company through each such date."}],"balance_after":44000,"derivative":{"underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001209191-19-039101","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119039101/doc4.xml","form_type":"4"}},{"id":3629347,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":21637,"kind":"person","name":"Collins Helen Louise","position":1,"cik":"0001701247","reported_name":"Collins Helen Louise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-02-27T19:58:21.000Z","date":"2019-02-25","kind":"grant","acquired":true,"shares":58000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest at a rate of one forty-eighth (1/48) per month following February 25, 2019, provided the reporting person provides services to the Company through each such date."}],"balance_after":58000,"derivative":{"exercise_price":11.97,"expiration_date":"2029-02-24","underlying":"Common Stock","underlying_shares":58000},"source":{"system":"sec-edgar","filing":"0001209191-19-014255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119014255/doc4.xml","form_type":"4"}}],"next_cursor":"2019-02-27T19:58:21.000000Z,3629347"}